fingolimod

Article Images

(Q425137)

English

chemical compound

FTY720
FTY-720

In more languages

default for all languages

No label defined

No description defined

Statements

type of chemical entity

0 references

chemical compound

0 references

0 references

chemical structure

Fingolimod structure.svg
512 × 134; 4 KB

0 references

307.251129 dalton

1 reference

language of work or name

Fingolimod (English)

3 October 2016

chemical formula

C₁₉H₃₃NO₂

1 reference

language of work or name

Fingolimod (English)

19 November 2016

canonical SMILES

CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N

1 reference

language of work or name

Fingolimod (English)

19 November 2016

defined daily dose

0.5 milligram

route of administration

oral administration

1 reference

https://www.whocc.no/atc_ddd_index/?code=L04AA27

active ingredient in

1 reference

14 February 2018

World Health Organisation international non-proprietary name

fingolimod (English)

2 references

language of work or name

fingolimod (English)

3 October 2016

Recommended INN: List 53

publication date

2005

Isaria sinclairii

1 reference

FTY720, a synthetic compound from Isaria sinclairii, inhibits proliferation and induces apoptosis in pancreatic cancer cells

medical condition treated

primary progressive multiple sclerosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

secondary progressive multiple sclerosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

relapsing-remitting multiple sclerosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

multiple sclerosis

1 reference

Drug Indications Extracted from FAERS

2 October 2018

multiple sclerosis

21 September 2010

Food and Drug Administration

1 reference

Inxight: Drugs Database

2 November 2018

https://drugs.ncats.io/drug/3QN8BYN5QF

https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022527s019lbl.pdf

significant drug interaction

(RS)-metoprolol

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

arsenic trioxide

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

levomepromazine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-hydroxyzine

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-citalopram

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-metoprolol

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-metoprolol

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

(RS)-metoprolol

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

decreased heart rate

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

shortened atrioventricular conduction time

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

sinus bradycardia

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

atrioventricular block

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

long QT syndrome

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

torsades de pointes

1 reference

sourcing circumstances

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

Potassium inwardly-rectifying channel, subfamily J, member 5

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

Transient receptor potential cation channel, subfamily M, member 7

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

17 August 2016

pregnancy category

Australian pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category C

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category E*

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Fingolimod

6 February 2018

subject has role

0 references

Commons category

Fingolimod

0 references

Identifiers

InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3

1 reference

language of work or name

Fingolimod (English)

19 November 2016

KKGQTZUTZRNORY-UHFFFAOYSA-N

2 references

language of work or name

Fingolimod (English)

19 November 2016

ChEBI release 2020-09-01

CAS Registry Number

2 references

Global Substance Registration System

language of work or name

fingolimod (English)

19 November 2016

CAS Common Chemistry

7 April 2021

https://commonchemistry.cas.org/detail?cas_rn=162359-55-9

KKGQTZUTZRNORY-UHFFFAOYSA-N

1 reference

language of work or name

Fingolimod (English)

19 November 2016

2 references

language of work or name

Fingolimod (English)

19 November 2016

matched by identifier from

KKGQTZUTZRNORY-UHFFFAOYSA-N

Reaxys registry number

7811195

1 reference

language of work or name

fingolimod (English)

3 October 2016

mapping relation type

2 references

language of work or name

FINGOLIMOD (English)

19 November 2016

matched by identifier from

International Chemical Identifier

InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3

1 reference

language of work or name

FINGOLIMOD (English)

19 November 2016

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

KKGQTZUTZRNORY-UHFFFAOYSA-N

UniChem compound ID

1 reference

DSSTox substance ID

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

matched by identifier from

KKGQTZUTZRNORY-UHFFFAOYSA-N

DSSTOX compound identifier

0 references

0 references

1 reference

language of work or name

Fingolimod (English)

publication date

17 November 2015

World Health Organisation international non-proprietary name numeric ID

1 reference

https://mednet-communities.net/inn/db/ViewINN.aspx?i=8341

Guide to Pharmacology Ligand ID

2 references

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

language of work or name

fingolimod (English)

19 November 2016

22 April 2020

https://www.guidetopharmacology.org/coronavirus.jsp

MeSH concept ID

0 references

1 reference

Global Substance Registration System

language of work or name

fingolimod (English)

19 November 2016

1 reference

matched by identifier from

KKGQTZUTZRNORY-UHFFFAOYSA-N

Human Metabolome Database ID

2 references

based on heuristic

inferred from InChIKey

matched by identifier from

KKGQTZUTZRNORY-UHFFFAOYSA-N

2 references

Global Substance Registration System

language of work or name

fingolimod (English)

19 November 2016

matched by identifier from

KKGQTZUTZRNORY-UHFFFAOYSA-N

MedlinePlus drug identifier

0 references

PatientsLikeMe treatment ID

0 references

1 reference

Global Substance Registration System

language of work or name

fingolimod (English)

19 November 2016

Probes And Drugs ID

0 references

1 reference

1 reference

language of work or name

fingolimod (English)

3 October 2016

electronic Essential Medicines List medicine ID

0 references

1 reference

Freebase Data Dumps

publication date

28 October 2013

Microsoft Academic ID

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

Römpp online ID

1 reference

imported from Wikimedia project

German Wikipedia

1 reference

Global Substance Registration System

language of work or name

fingolimod (English)

19 November 2016

WikiProjectMed ID

0 references

Sitelinks

Wikipedia(22 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(1 entry)

commonswiki Category:Fingolimod

Retrieved from "https://www.wikidata.org/w/index.php?title=Q425137&oldid=2186675349"